Pfizer, GM, AIG - what to expect?
Pfizer (reporting on May 4, 17:00 GMT+3)
Expected EPS: $0.79
This century-old pharma company gained global attention on vaccine production last autumn. At the peak of investor interest, it reached as high as $43 per share – heights unseen since the middle of 2019. Although the stock price was quick to cede the gains later on, it’s still in an uptrend. A positive Q1’2021 report may well push it to those heights again - fundamentally, there are all the reasons to expect strong performance.
Technically, if the report is better than the forecasts, the stock will likely rise to $41 and take $43 as a mid-term upside objective.
Remember you can trade stocks in Metatrader 5 or FBS Trader app!
General Motors (reporting on May 5, 14:30 GMT+3)
Expected EPS: $1.01
This pillar of the US vehicle production industry not only managed to recover from the virus hit but reached strategically new highs of $60 – as high as never, at least over the course of the last ten years. The stock is now in a local drop so a strong report will push it back upwards to establish itself at new heights.
During the previous two quarters, GM managed to beat the expectations of observers brings better-than-thought results. In absolute figures, performance of Q1'2021 is expected to be lower than that of the second part of 2020. Hence, there is a big potential for GM to surprise the market and send the stock soar.
AIG (reporting on May 6, 15:30 GMT+3)
Expected EPS: $0.99
This financial and insurance corporation has not been doing well – it’s one of the companies that haven’t recovered the virus losses. Meeting March 2020 at the ranges of $50, this stock dropped as low as $20. Currently, it’s on the way upwards – right at the gates of the pre-virus level. Forecast-beating data will help it make a 100% recovery and move further upwards.
Last time, AIG's results were lower than the forecasts - that's one of the reason why observers are quite modest with their expectations this time. In the meantime, if AIG manages to outperform, that may be a real boost to its stock - tactically, it may aim at the pre-virus high of $56. That's only in case the data is exceptionally strong, though, which is not that likely. So, let's see the report out and watch the market reaction.
